Michael Berry
Directeur Technique/Scientifique/R&D chez EVEREST MEDICINES LIMITED
Profil
Michael Berry is currently the Chief Technology Officer at Everest Medicines Ltd.
He previously worked as the Senior Director of Bioprocess Development at Portola Pharmaceuticals, Director at ARCA biopharma, Director of Manufacturing Sciences & Technology at Novartis Vaccines & Diagnostics SL, and Vice President at Dynavax Technologies Corp.
He is also the Chief Technical Operations Officer at Clover Biopharmaceuticals Ltd.
Berry received his undergraduate degree from De Montfort University, his graduate degree from The University of Manchester, and his doctorate from the University of Manitoba.
Postes actifs de Michael Berry
Sociétés | Poste | Début |
---|---|---|
EVEREST MEDICINES LIMITED | Directeur Technique/Scientifique/R&D | 15/06/2023 |
Anciens postes connus de Michael Berry
Sociétés | Poste | Fin |
---|---|---|
DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01/08/2017 |
PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2015 |
Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | 01/09/2013 |
ARCA BIOPHARMA, INC. | Directeur/Membre du Conseil | 01/05/2009 |
CLOVER BIOPHARMACEUTICALS, LTD. | Directeur Technique/Scientifique/R&D | - |
Formation de Michael Berry
De Montfort University | Undergraduate Degree |
The University of Manchester | Graduate Degree |
University of Manitoba | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
ARCA BIOPHARMA, INC. | Health Technology |
DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
EVEREST MEDICINES LIMITED | Health Technology |
Entreprise privées | 2 |
---|---|
Novartis Vaccines & Diagnostics SL | |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |